Key result
Routine monitoring of anti-factor Xa concentrations in obese patients receiving low-molecular-weight heparin is not warranted, as concentrations are not strongly associated with thrombosis or hemorrhage.
Why the study?
Does routine monitoring of anti-factor Xa activity improve clinical outcomes or predict thrombosis/hemorrhage in obese patients receiving LMWH?
Population
Obese patients receiving low-molecular-weight heparin therapy for thromboprophylaxis or treatment of venous…
Design
Systematic_review
Authors
Loading...
Routine anti-Xa monitoring lacks support for LMWH in obesity; reinforces weight-based dosing without routine assays and leaves targeted use open for study.
Systematic Review
Does routine monitoring of anti-factor Xa activity improve clinical outcomes or predict thrombosis/hemorrhage in obese patients receiving LMWH?
Routine monitoring of anti-factor Xa concentrations in obese patients receiving LMWH is not warranted based on current evidence, as it does not strongly predict thrombosis or hemorrhage.
Egan et al. (2015) conducted a systematic review in Obesity requiring low-molecular-weight heparin therapy. Routine anti-factor Xa monitoring vs. Standard weight-based dosing without routine monitoring was evaluated on Association of anti-Xa concentrations with clinical outcomes (thrombosis or hemorrhage). Routine monitoring of anti-factor Xa concentrations in obese patients receiving low-molecular-weight heparin is not warranted, as concentrations are not strongly associated with thrombosis or hemorrhage.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: